Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotavirus W179-9 vaccine - Merck & Co

Drug Profile

Rotavirus W179-9 vaccine - Merck & Co

Alternative Names: Pentavalent-rotavirus-vaccine-W179-9-Merck-and-Co; PRV-Merck-and-Co; RotaTeq; Rotavirus-vaccine-live-oral-pentavalent-W179-9-Merck-and-Co; Rotavirus-W179-9-vaccine-Merck-and-Co; RV5; V260

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Chongqing Zhifei Biological Products; Merck & Co
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 05 May 2022 Merck Sharp & Dohme initiates enrollment in a phase III trial in Rotavirus infections (In infants, In volunteers) (PO) in August 2004 (NCT00092456)
  • 08 May 2021 Merck Sharp and Dohme completes a phase III trial for Rotavirus infection (Prevention, In Infants) in China(NCT04481191)
  • 25 Aug 2020 Merck Sharp and Dohme initiates a phase III trial for Rotavirus infection (Prevention, In Infants) in China(NCT04481191)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top